6 days Ago By ABMN Staff
Geode Capital Management LLC raised its holdings in Geron Co. ( NASDAQ:GERN – Free Report ) by 0.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The firm owned 13,141,514 shares of the biopharmaceutical company’s stock after purchasing an additional 73,515 shares during the quarter. Geode Capital Management LLC owned 2.17% of Geron worth $46,531,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in GERN. Verition Fund Management LLC increased its holdings in Geron by 256.6% during the third quarter.
Verition Fund Management LLC now owns 47,455 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 34,146 shares during the last quarter. Stifel Financial Corp grew its position in shares of Geron by 30.7% during the 3rd quarter.
Stifel Financial Corp now owns 47,477 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 11,149 shares during the period. Barclays PLC increased its stake in shares of Geron by 114.9% during the 3rd quarter.
Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock worth $5,902,000 after purchasing an additional 694,931 shares during the last quarter. World Investment Advisors LLC raised its holdings in shares of Geron by 10,151.4% in the 3rd quarter.
World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company’s stock worth $4,674,000 after purchasing an additional 1,019,510 shares during the period. Finally, Franklin Resources Inc. lifted its stake in Geron by 461.
4% in the third quarter. Franklin Resources Inc. now owns 79,923 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 65,687 shares during the last quarter.
73.71% of the stock is owned by hedge funds and other institutional investors. Analysts Set New Price Targets Several brokerages have issued reports on GERN.
HC Wainwright restated a “neutral” rating on shares of Geron in a research note on Wednesday, March 12th. Scotiabank lowered their price objective on Geron from $6.00 to $4.
00 and set a “sector outperform” rating on the stock in a research note on Thursday, February 27th. Stifel Nicolaus reduced their target price on shares of Geron from $8.00 to $4.
00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Needham & Company LLC reissued a “buy” rating and issued a $5.00 price target on shares of Geron in a research report on Wednesday, March 12th.
Finally, B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $3.50 to $2.
00 in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $5.
75. Geron Stock Performance NASDAQ GERN opened at $1.32 on Tuesday.
The stock has a market capitalization of $840.71 million, a PE ratio of -4.13 and a beta of 0.
66. Geron Co. has a 1 year low of $1.
19 and a 1 year high of $5.34. The company’s 50 day simple moving average is $1.
89 and its two-hundred day simple moving average is $3.10. The company has a debt-to-equity ratio of 0.
04, a current ratio of 2.89 and a quick ratio of 2.74.
Geron ( NASDAQ:GERN – Get Free Report ) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.
04). The business had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.
29 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.
53%. Analysts predict that Geron Co. will post -0.
25 earnings per share for the current fiscal year. Geron Profile ( Free Report ) Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Featured Stories Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter ..
